Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 19;6(4):153-159.
doi: 10.1016/j.jimed.2023.09.001. eCollection 2023 Nov.

Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer

Yasaman Anbari  1 , Floortje E Veerman  1 , Grace Keane  1 , Arthur J A T Braat  1 , Maarten L J Smits  1 , Rutger C G Bruijnen  1 , Wenle Tan  2 , Ye Li  2 , Feng Duan  2 , Marnix G E H Lam  1
Affiliations

Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer

Yasaman Anbari et al. J Interv Med. .

Abstract

Liver malignancy, including primary liver cancer and metastatic liver cancer, has become one of the most common causes of cancer-related death worldwide due to the high malignant degree and limited systematic treatment strategy. Radioembolization with yttrium-90 (90Y)-loaded microspheres is a relatively novel technology that has made significant progress in the local treatment of liver malignancy. The different steps in the extensive work-up of radioembolization for patients with an indication for treatment with 90Y microspheres, from patient selection to follow up, both technically and clinically, are discussed in this paper. It describes the application and development of 90Y microspheres in the treatment of liver cancer.

Keywords: Metastatic liver cancer; Primary liver cancer; Selective internal radiation therapy; Trans-arterial radioembolization; Yttrium-90 microspheres.

PubMed Disclaimer

Conflict of interest statement

Feng Duan is the youth editorial board member for Journal of Interventional Medicine and was not involved in the editorial review or the decision to publish this article. All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The workflow of radioembolization.
Fig. 2
Fig. 2
Patient with HCC who received radioembolization with 90Y glass microspheres. (a) The baseline image (MRI) demonstrated enhancing hepatocellular carcinoma in segment V/VI. (b) PET/CT image immediately after the treatment, 90Y glass microspheres were selectively injected into the right hepatic artery. As shown, the microspheres are concentrated in the tumor located in segment V/VI. (c) Follow-up MRI 2 months after radioembolization showing complete response to the treatment as the tumor is no longer enhanced.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Singh P., Anil G. Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imag. 2014;13:645–657. - PMC - PubMed
    1. Weber M., Lam M., Chiesa C., et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imag. 2022;49:1682–1699. - PMC - PubMed
    1. Dewaraja Y.K., Devasia T., Kaza R.K., et al. Prediction of tumor control in 90Y radioembolization by logit models with PET/CT-based dose metrics. J Nucl Med. 2020;61:104–111. - PMC - PubMed
    1. Kim S.P., Cohalan C., Kopek N., et al. A guide to 90Y radioembolization and its dosimetry. Phys Med. 2019;68:132–145. - PubMed
    1. Levillain H., Bagni O., Deroose C.M., et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imag. 2021;48:1570–1584. - PMC - PubMed

LinkOut - more resources